ABOUT
Our Impact
BioCanRx is focused on supporting translational research that is bringing Canadian developed and manufactured therapeutics to cancer patients in Canada.
By funding research that is indication agnostic and focusing on the most challenging part of the research process – moving initial discovery to the clinic – our funding has the potential to have broad impact and change the landscape of cancer treatment in Canada.
Our Broader Impact
Explore the many ways BioCanRx is advancing cancer immunotherapy in Canada and beyond.
Click any category below to jump to that section.
Research
By providing non-dilutive funding at the most critical stage of research we are helping new therapeutics developed in Canada move through the translational research stage to the clinic – where they can benefit patients.
Our pipeline approach ensures researchers have the funding and resources they need to develop, produce and deliver novel therapeutics here in Canada.
Novel
Therapeutics
Patents & Patent
Application
Research
Publications
Industry
Partners
Patients
Patients are at the heart of our work. Our investments are cancer agnostic and look to support research and innovation that will have the greatest benefit for the largest number of patients. Across our network research knowledge sharing is encouraged, and patients are engaged in our research projects to ensure their perspectives and experiences are taken into consideration. Working with patient organizations we are ensuring that we are responding to the needs of Canadian cancer patients.
Number of patients treated
Current Studies with Patient Partner Engagement
Cancer Community Partners
Funding & Leverage
By providing funding and resources – biomanufacturing and commercialization support – BioCanRx is helping to derisk innovation for future investors including pharmaceuticals and the health care system. Our model attracts additional funders who recognize the strength of project selection process and the excellence of our research network. This will ensure the development and manufacture of cancer immunotherapy treatments happens here in Canada – critical to ensuring Canadian patients with cancer have access to new and effective treatments when they need them.
Total BioCanRx Investment
$50M+
Total Partner Funding
$150M+
International Impact
Commercialization
The BioCanRx translational ecosystem approach uses a staged pipeline that yields tangible results. Projects are able to advance along the development pipeline from pre-clinical development to clinical evaluation, and have access to commercialization expertise – all contributing to derisking the commercialization process for future investment. The result? Canadian innovations are able to stay here in Canada – benefiting our economy and patients.